EHang Announces Progress in EH216-S Type Certification Process as It Enters into More In-Depth Review Phase
30 sept. 2022 10h07 HE | EHang Holdings Limited
GUANGZHOU, China, Sept. 30, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform...
Freeline_Logo_Red_RGB.jpg
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 sept. 2022 17h30 HE | Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...
EHang NasdaqListed Logo.png
EHang Reports Second Quarter 2022 Unaudited Financial Results
18 août 2022 05h00 HE | EHang Holdings Limited
–   Total Revenues Up 152.5% QoQ–   High Quarterly Gross Margin of 67.1%–   Indicative Facilities of RMB1 Billion by Agricultural Bank of China Guangzhou Branch–   Increasing Deliveries in China and...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
09 août 2022 07h00 HE | Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
EHang NasdaqListed Logo.png
EHang to Report Second Quarter 2022 Unaudited Financial Results on Thursday, August 18, 2022
08 août 2022 08h00 HE | EHang Holdings Limited
GUANGZHOU, China, Aug. 08, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline_Logo_Red_RGB.jpg
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 août 2022 16h01 HE | Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
EH216 Completes Demo Flight Tour in 4 Japanese Cities to Mark 1,000-Day Countdown of Expo 2025 Osaka, Kansai
22 juil. 2022 08h38 HE | EHang Holdings Limited
GUANGZHOU, China, July 22, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline_Logo_Red_RGB.jpg
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
21 juil. 2022 07h00 HE | Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
FronteraTherapeutics_Logo_300dpi.jpg
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
19 juil. 2022 08h00 HE | Frontera Therapeutics
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may...
Freeline_Logo_Red_RGB.jpg
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2022 16h01 HE | Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...